Akebia Therapeutics, Inc. Net Income Loss

• Akebia Therapeutics, Inc. showed an increase of +92.3% in Net Income Loss from 2024 to 2025.
• This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Akebia Therapeutics, Inc.'s Net Income Loss has grown by 34.8%.
• Historical annual values: Fiscal year 2025: -$5.35 million | Fiscal year 2024: -$69.41 million | Fiscal year 2023: -$51.93 million | Fiscal year 2022: -$94.23 million | Fiscal year 2021: -$282.84 million | Fiscal year 2020: -$383.46 million | Fiscal year 2019: -$279.66 million | Fiscal year 2018: -$143.59 million | Fiscal year 2017: -$73.67 million | Fiscal year 2016: -$135.75 million | Fiscal year 2015: -$60.72 million | Fiscal year 2014: -$37.03 million | Fiscal year 2013: -$13.17 million | Fiscal year 2012: -$8.20 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026